• September 16, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has been named among the top 10 on Working Mother magazine’s "100 Best Companies for Working Mothers" list. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as child care, flexibility, advancement and paid family leave. “Zoetis is honored to be named one of Working Mother magazine’s top tenmore...
  • September 3, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted a conditional license for a vaccine to help fight porcine epidemic diarrhea virus (PEDv) in pigs. The two-dose inactivated vaccine, licensed for use in healthy pregnant female pigs (sows and gilts), is designed to help them develop antibodies which can be transmitted to their newborn piglets. Zoetis anticipates the vaccine will be available tomore...
  • August 27, 2014
    DURHAM, N.C., August 27, 2014 – Zoetis Inc. has obtained a full license from the U.S. Department of Agriculture (USDA) to sell Poulvac® Bron GA 08, the first commercially available vaccine to reduce disease caused by Georgia 2008 (GA 08) Type infectious bronchitis virus (IBV) in poultry.Poulvac® Bron GA 08, a live vaccine, is licensed for vaccination of healthy chickens at one day of age or older as an aid in the reduction of disease caused by GA 08. The vaccine was licensed based on clinicalmore...
  • August 20, 2014
    FLORHAM PARK, N.J., Aug. 20, 2014 — Fostera™ PCV MH — the porcine circovirus (PCV) and Mycoplasma hyopneumoniae (M. hyo) combination vaccine that was built from the ground up by Zoetis — now has the longest demonstrated duration of immunity (DOI) to help protect pigs from porcine circovirus-associated disease (PCVAD) caused by PCV Type 2 (PCV2). The U.S. Department of Agriculture has granted the combination vaccine the extended label claim of at least 23 weeks of protection against PCV2, whichmore...
  • August 20, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 18, in London, UK. Juan Ramón Alaix, Chief Executive Officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 6:25 a.m. EDT (11:25 a.m. BST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visitingmore...
  • August 14, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Paul Herendeen as its new Executive Vice President and Chief Financial Officer (EVP & CFO), completing a leadership transition that began in April. Herendeen has spent the last 16 years in CFO roles at health care companies Warner Chilcott and MedPointe, building on a successful career in finance, banking and private equity partnerships. In his role at Zoetis, Herendeen willmore...
  • August 13, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 2:05 p.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/more...
  • August 5, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced it will hold its inaugural Investor Day for financial analysts on Tuesday, Nov. 18, at the New York Stock Exchange. The event, hosted by Chief Executive Officer Juan Ramón Alaix and other members of the Zoetis executive team, will be used to provide investors with information on the company’s strategy, capabilities and value proposition, as well as the overall animal health industry.more...
  • August 5, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2014. The company reported revenue of $1.2 billion for the second quarter of 2014, an increase of 4% from the second quarter of 2013. Revenue reflected an operational2 increase of 6%, with foreign currency having a negative impact of 2 percentage points. Net income for the second quarter of 2014 was $136 million, or $0.27 per diluted share, anmore...
  • July 31, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) declared a third quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on Tuesday, Sept. 2, 2014, to holders of record on Wednesday, Aug. 20, 2014. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 yearsmore...